Get the Stockscreener App
2.405
0.21%
0.005
Nrx Pharmaceuticals Inc stock is traded at $2.405, with a volume of 131.46K.
It is up +0.21% in the last 24 hours and up +2.33% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.41
Open:
$2.37
24h Volume:
131.46K
Relative Volume:
0.27
Market Cap:
$71.35M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.6013
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-8.17%
1M Performance:
+2.33%
6M Performance:
-28.55%
1Y Performance:
-31.20%
1-Day Range:
$2.36
$2.43
1-Week Range:
$2.359
$2.765
52-Week Range:
$1.58
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.41 | 71.35M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.91 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.61 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.65 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.52 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.23 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network - Digital Journal
NRx Pharmaceuticals and neurocare group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and Other Mental Health Afflictions - citybiz
D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions - Investing News Network
NRx and neurocare partner to create nationwide neuroplastic care network - Investing.com
NRx and neurocare partner to create nationwide neuroplastic care network By Investing.com - Investing.com Australia
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions - The Manila Times
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG - GlobeNewswire
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Breakout Zone: Is NRx Pharmaceuticals Inc Equity Warrant stock in correction or buying zone2025 Growth vs Value & Safe Entry Trade Signal Reports - moha.gov.vn
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals Completes Debt Repayment, Ends 2025 Debt-Free - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 38.2% in December - MarketBeat
NRX Pharmaceuticals, Inc. Eliminates All Balance Sheet Debt - TradingView — Track All Markets
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - Sentinel-Standard
NRx’s preservative-free ketamine reaches FDA review as company targets 2026 launch - MSN
New to The Street Broadcasts Nationwide Tonight on Bloomberg Television Featuring NeOnc ($NTHI), Metaterra Holdings Inc., CISO Global ($CISO), and NRx Pharmaceuticals ($NRXP) - Idaho Statesman
Earnings Update: Why hedge funds are buying NRx Pharmaceuticals Inc. stockPortfolio Update Summary & Risk Controlled Swing Trade Alerts - moha.gov.vn
NRX Pharmaceuticals Earnings Notes - Trefis
Bearish Setup: Will NRx Pharmaceuticals Inc. Equity Warrant stock outperform value stocksJuly 2025 Opening Moves & Daily Volume Surge Signals - moha.gov.vn
Is NRx Pharmaceuticals Inc. stock a top momentum play2025 Buyback Activity & Safe Capital Investment Plans - ulpravda.ru
Will NRx Pharmaceuticals Inc. stock pay special dividends2025 Retail Activity & Low Drawdown Momentum Ideas - Улправда
Can NRx Pharmaceuticals Inc. stock beat market expectations this quarterEarnings Summary Report & Growth Oriented Trading Recommendations - DonanımHaber
Published on: 2025-12-19 15:23:52 - DonanımHaber
Why NRx Pharmaceuticals Inc. Equity Warrant stock is a value investor pickWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - DonanımHaber
Can NRx Pharmaceuticals Inc. stock withstand economic slowdownWatch List & Technical Buy Zone Confirmations - DonanımHaber
Is NRx Pharmaceuticals Inc. stock a buy in volatile markets2025 Earnings Surprises & Real-Time Stock Price Movement Reports - Улправда
NRx Pharmaceuticals (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion - Digital Journal
Why NRx Pharmaceuticals Inc. Equity Warrant stock could see breakout soonJuly 2025 Short Interest & Stepwise Trade Execution Plans - Улправда
What momentum indicators show for NRx Pharmaceuticals Inc. stockTrade Risk Summary & High Return Stock Watch Alerts - Улправда
NRx Pharmaceuticals clears remaining $5.4 million debt By Investing.com - Investing.com Nigeria
Can NRx Pharmaceuticals Inc. stock rebound after recent weakness2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - Улправда
NRx Pharmaceuticals Announces Elimination of All Balance Sheet Debt Following Equity Conversion - citybiz
NRx Pharmaceuticals announces elimination of all balance sheet debt following equity conversion - Investing News Network
NRx Pharmaceuticals clears remaining $5.4 million debt - Investing.com
NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026 - Quiver Quantitative
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion - marketscreener.com
NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at HC Wainwright - MarketBeat
NRXP: HC Wainwright & Co. Reiterates Buy Rating with $40 Target - GuruFocus
HC Wainwright & Co. Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq
Market Outlook: Does NRx Pharmaceuticals Inc stock trade at a discount to peersJuly 2025 Drop Watch & Stock Timing and Entry Methods - moha.gov.vn
[S-3/A] NRX Pharmaceuticals, Inc. Amended Shelf Registration Statement | NRXP SEC FilingForm S-3/A - Stock Titan
NRx Eyes Faster Commercial Path as NRX-101 Moves Into TMS-Enhanced Depression Treatment - MyChesCo
NRx’s Preservative-Free Ketamine Reaches FDA Review as Company Targets 2026 Launch - MyChesCo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Gross profit of NRX Pharmaceuticals, Inc. – HAM:B1Q - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Cash from financing activities of NRX Pharmaceuticals, Inc. – HAM:B1Q - TradingView
Is NRx Pharmaceuticals Inc. stock a bargain at current levelsMarket Rally & Weekly Top Stock Performers List - Newser
BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals amends IND filing for NRX-101 to include use for TMS - MSN
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):